Skip to content
Search AI Powered

Latest Stories

Mixed views on benefits of cannabis oil products

By Nadeem Badshah

TOP pharmacists are divided on the benefits of cannabis oil products being sold to treat pain.


Around 1.3 million UK consumers spend £300 million a year on CBD goods, research has shown, with a number of specialist stores opening in high streets across the country.

Cannabidiol, or CBD, is a chemical found in the cannabis plant. The products are legal if sold as a food supplement but require medical permission if offered as a medicine.

It has led to a string of CBD medical marijuana card online doctor infused products including oils, muscle balms, anti-ageing creams and sex lubricants. A Hemp and CBD Expo is taking place at the NEC in Birmingham on February 29-March 1.

Pharmacist Nader Siabi has urged people to buy them from chemists to get advice on whether it is dangerous to take with other medicine and to do research on the CBD content of products.

Siabi, from the North East London Pharmaceutical Committee, told Eastern Eye: "Some companies made claims they were not able to substantiate but one produced the lab data and batch numbers.

"There is no scientific claims for the benefits but people who use them say it is working. We put CBD in the pharmacy and from the first week people are buying them.

"We are selling drugs, sprays and balm for joint pains for example. We see people coming for repeat purchases, they have found some benefit.

"Whether it is a placebo effect or it is helping them, I believe in it 100 per cent now due to patient feedback.

"You have to do your due diligence and ensure patients have the necessary information about drug interactions [mixing with other medicine]."

CBD products contain a non-psychoactive chemical found in the hemp plant. It has become trendy among people in the past year over claims it helps with pain and insomnia.

Between 2002 and 2012 there were nine published studies on the use of CBD for the treatment of pain.

By 2017, there had been 30 with most showing potential benefits for pain relief but the studies involved small participant numbers and mostly rats.

Vikesh Patel, who owns four pharmacists in south east England, said he is sceptical about CBD.

He told Eastern Eye: "There is no evidence of the product claims on anxiety, constipation.

"If it's that great why haven't they done a clinical trial?

"If the user is not intellectual and learned enough, they can be fobbed off.

"We are selling CBD oral drops, skin creams and sprays out of business need and we go with companies that have some data and do not sell to under 18s.

"Before it was homeopathic medicines, there was no evidence for it, and they clamped down on it being sold in pharmacies."

Since last October, cannabis-based products can be prescribed by specialist hospital doctors in cases of children with rare, severe forms of epilepsy and adults with vomiting or nausea caused by chemotherapy or muscle stiffness from multiple sclerosis.

A spokesman for the National Pharmacy Association said it would welcome more research and guidance that makes it easier for manufacturers, health care professionals, retailers and consumers to make informed choices.

“Our advice to pharmacists considering whether to stock non-medicinal CBD products is to ensure they are acting legally and putting the needs of patients first – which is the same advice we’d give about all other products sold or supplied in pharmacies.

"In the case of non-medicinal CBD products, pharmacists should take account of current Home Office guidance.

“Currently the evidence about the long term effects of these products is limited and the regulations are complex."

Kings College London (KCL) secured funding to carry out a large-scale trial to test whether CBD could be useful in treating young people at high risk of developing psychosis.

Dr Sagnik Bhattacharyya, from KCL's psychiatry, psychology and neuroscience unit said few of the claims for CBD's effects have been tested but scientists are looking whether large doses could help treat severe mental health problems.

He added: "We have carried out a couple of studies where we show that a single 600mg dose of cannabidiol can normalise brain function in key regions we know are abnormal in people with psychosis."

More For You

FCA warns against regulatory 'race to bottom' in growth push
Nikhil Rathi
TOLGA AKMEN

FCA warns against regulatory 'race to bottom' in growth push

FINANCIAL REGULATOR has cautioned against compromising regulatory standards while attempting to boost economic growth, revealing the delicate balancing act facing Britain's financial oversight.

In a frank discussion with MPs, the Financial Conduct Authority (FCA) leadership highlighted the challenges of their expanded mandate to promote business competitiveness alongside consumer protection, reported the Times.

Keep ReadingShow less
Sanjay Bhandari's extradition appeal opens in London
Sanjay Bhandari

Sanjay Bhandari's extradition appeal opens in London

SANJAY BHANDARI, a consultant in the defence sector wanted in India on alleged tax evasion and money-laundering charges, began an appeal in the High Court in London against his extradition order.

The 62-year-old businessman had won permission to appeal against a November 2022 Westminster Magistrates’ Court ruling clearing his extradition earlier this year.

Keep ReadingShow less
Rupert Murdoch looks on as he walks on the day of the hearing on the contentious matter of succession of Rupert Murdoch's global television and publishing empire, in Reno, Nevada, US, September 23, 2024. (Photo: Reuters)
Rupert Murdoch looks on as he walks on the day of the hearing on the contentious matter of succession of Rupert Murdoch's global television and publishing empire, in Reno, Nevada, US, September 23, 2024. (Photo: Reuters)

Murdoch's bid to secure eldest son's control of media empire fails

RUPERT MURDOCH’s attempt to secure control of his media empire for his eldest son, Lachlan, has reportedly failed, according to a US news report on Monday.

The Murdoch family, which oversees influential outlets like Fox News, The Wall Street Journal, and various British and Australian media organisations, has often been compared to the fictional dynasty in the TV series Succession. Like the show, real-life disputes within the Murdoch family have centred on control of the business after Rupert Murdoch’s death.

Keep ReadingShow less
Kamlesh Pattni faces UK sanctions for illicit gold trade
Pattni stands accused of central involvement in the infamous Goldenberg scandal. (Representational image: iStock)

Kamlesh Pattni faces UK sanctions for illicit gold trade

THE UK and US have imposed financial sanctions on Kamlesh Pattni, a British-Kenyan businessman with a controversial financial history. The punitive measures target Pattni and four of his close family members, including his wife and brother-in-law, reported the BBC.

The sanctions, announced by the UK Foreign, Commonwealth and Development Office, will result in the immediate freezing of assets, representing a significant intervention in what officials describe as a complex network of illicit gold trading spanning multiple African nations.

Keep ReadingShow less
Sanjay Malhotra speaks during the 67th Foundation Day of the Directorate of Revenue Intelligence (DRI) in New Delhi on December 4, 2024. (Photo: Getty Images)
Sanjay Malhotra speaks during the 67th Foundation Day of the Directorate of Revenue Intelligence (DRI) in New Delhi on December 4, 2024. (Photo: Getty Images)

India appoints Sanjay Malhotra as new central bank governor

INDIA has appointed Sanjay Malhotra, a senior finance ministry bureaucrat, as the new governor of its central bank, the Reserve Bank of India (RBI).

The announcement was made on Monday, a day before the term of outgoing governor Shaktikanta Das was set to expire.

Keep ReadingShow less